Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events

Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor. In all five patients haematological and biochemical parameters...

Descripción completa

Detalles Bibliográficos
Autores principales: Dragoni, Francesco, Chiarotti, Flavia, Iori, Anna Paola, La Rocca, Ursula, Cafolla, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196560/
https://www.ncbi.nlm.nih.gov/pubmed/30377413
http://dx.doi.org/10.1186/s12959-018-0181-5
_version_ 1783364574750179328
author Dragoni, Francesco
Chiarotti, Flavia
Iori, Anna Paola
La Rocca, Ursula
Cafolla, Arturo
author_facet Dragoni, Francesco
Chiarotti, Flavia
Iori, Anna Paola
La Rocca, Ursula
Cafolla, Arturo
author_sort Dragoni, Francesco
collection PubMed
description Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor. In all five patients haematological and biochemical parameters and adverse events were evaluated for a period of twelve months. Therapy with rivaroxaban was well tolerated in all cases and one patient showed a significant reduction of bleeding and transfusion requirement. All patients obtained a significant reduction in days of hospitalization with a consequent improvement in their quality of life after rivaroxaban treatment.
format Online
Article
Text
id pubmed-6196560
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61965602018-10-30 Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events Dragoni, Francesco Chiarotti, Flavia Iori, Anna Paola La Rocca, Ursula Cafolla, Arturo Thromb J Letter to the Editor Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor. In all five patients haematological and biochemical parameters and adverse events were evaluated for a period of twelve months. Therapy with rivaroxaban was well tolerated in all cases and one patient showed a significant reduction of bleeding and transfusion requirement. All patients obtained a significant reduction in days of hospitalization with a consequent improvement in their quality of life after rivaroxaban treatment. BioMed Central 2018-10-22 /pmc/articles/PMC6196560/ /pubmed/30377413 http://dx.doi.org/10.1186/s12959-018-0181-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Dragoni, Francesco
Chiarotti, Flavia
Iori, Anna Paola
La Rocca, Ursula
Cafolla, Arturo
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
title Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
title_full Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
title_fullStr Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
title_full_unstemmed Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
title_short Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
title_sort antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196560/
https://www.ncbi.nlm.nih.gov/pubmed/30377413
http://dx.doi.org/10.1186/s12959-018-0181-5
work_keys_str_mv AT dragonifrancesco antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents
AT chiarottiflavia antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents
AT ioriannapaola antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents
AT laroccaursula antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents
AT cafollaarturo antithrombotictherapywithrivaroxabaninfivepatientswithparoxysmalnocturnalhaemoglobinuriaandthromboticevents

Ejemplares similares